Therapeutic agent for amyotrophic lateral sclerosis and composition for treatment
A therapeutic agent for amyotrophic lateral sclerosis including a compound represented by Formula (1) [in Formula (1), R 1 each independently represents an alkyl group having 1 to 6 carbon atoms or 4-hydroxyphenethyl group, and n represents an integer of 1 to 3], a pharmaceutically acceptable salt thereof, or a solvate thereof, as an effective ingredient.
1 . A method of treating sporadic amyotrophic lateral sclerosis (ALS), or familial ALS having a mutation in the FUS gene and/or TAR DNA-binding protein 43 kDa (TDP-43) gene, after onset of the ALS phenotype, comprising:
administering an effective amount of a compound represented by Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof to a patient in need thereof
in Formula (1), R 1 each independently represents an alkyl group having 1 to 6 carbon atoms or a 4-hydroxyphenethyl group, and n represents an integer of 1 to 3.
2 . The method according to claim 1 , wherein n in Formula (1) is 2.
3 . The method according to claim 1 ,
wherein R 1 in Formula (1) is an n-propyl group.
4 . The method according to claim 1 ,
wherein the compound represented by Formula (1) is 4-(2-di-n-propylaminoethyl)-2 (3H)-indolone.
5 . The method according to claim 1 ,
wherein the pharmaceutically acceptable salt of the compound represented by Formula (1) is 4-(2-di-n-propylaminoethyl)-2 (3H)-indolone hydrochloride.
6 . A method of treating sporadic ALS, or familial ALS having a mutation in the FUS gene and/or TDP-43 gene, after onset of the ALS phenotype, comprising:
administering an effective amount of a composition to a patient in need thereof, wherein the composition includes a compound represented by Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof and a pharmaceutically acceptable carrier
in Formula (1), R 1 each independently represents an alkyl group having 1 to 6 carbon atoms or a 4-hydroxyphenethyl group, and n represents an integer of 1 to 3.